申请人:Sumitomo Chemical Company, Limited
公开号:US04263304A1
公开(公告)日:1981-04-21
Novel indoloisoquinoline derivatives of the formula, ##STR1## wherein R.sub.1 and R.sub.4 are each hydrogen, a halogen, nitro or C.sub.1-4 alkoxy and R.sub.2 and R.sub.3 are each hydrogen, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, a C.sub.3-6 cycloalkyl-C.sub.1-3 alkyl or a group of the formula, ##STR2## or -A-O-B wherein A is a C.sub.1 -C.sub.7 alkylene; R.sub.5 and R.sub.6 are each hydrogen or C.sub.1-4 alkyl, or, when taken together with the adjacent nitrogen atom, may form a 5- or 6-membered heterocyclic ring and B is hydrogen, C.sub.1-4 alkyl, C.sub.2-4 alkenyl or C.sub.2-4 alkanoyl, provided that, when both R.sub.1 and R.sub.4 are hydrogen and R.sub.3 is methyl, then R.sub.2 can not be hydrogen, have potent anti-tumor activities.
新型吲哚异喹啉衍生物的化学式为##STR1##其中R.sub.1和R.sub.4分别为氢、卤素、硝基或C.sub.1-4烷氧基,R.sub.2和R.sub.3分别为氢、C.sub.1-4烷基、C.sub.2-4烯基、C.sub.3-6环烷基-C.sub.1-3烷基或具有下列化学式的基团##STR2##或-A-O-B,其中A为C.sub.1-C.sub.7烷基;R.sub.5和R.sub.6分别为氢或C.sub.1-4烷基,或者与相邻的氮原子一起形成5-或6-成员杂环环,并且B为氢、C.sub.1-4烷基、C.sub.2-4烯基或C.sub.2-4烷酰基,但当R.sub.1和R.sub.4均为氢且R.sub.3为甲基时,则R.sub.2不能为氢,具有强效的抗肿瘤活性。